Can Compass Pathways Justify Its Valuation Before the FDA Clock Actually Starts?

Compass Pathways (NASDAQ: CMPS) reports first-quarter 2026 earnings tomorrow, May 13, before market open, with analysts expecting a loss of $0.45 per share. The central question is whether the clinical-stage biotech can demonstrate progress in its COMP360 psilocybin program for treatment-resistant depression while managing cash burn—a critical concern after last quarter's disappointing $0.59 loss that missed estimates by 44%. With the stock up 50% from its 200-day moving average and analyst sentiment strengthening sharply, investors are looking for signs that the company's regulatory pathway and trial execution are back on track.

Part 1: Earnings Preview

Compass Pathways is a clinical-stage biotechnology company developing COMP360, an investigational synthesized psilocybin therapy for treatment-resistant depression (TRD), which has received Breakthrough Therapy designation from the FDA. The company is pioneering a new treatment paradigm focused on rapid and durable responses in mental health conditions where existing therapies have failed.

Earnings Expectations: Compass reports Q1 2026 results on May 13 before market open, with the consensus estimate calling for a loss of $0.45 per share from 6 analysts. The company most recently reported a Q4 2025 loss of $0.59 per share on March 24, which badly missed the $0.41 estimate. Year-over-year, the Q1 2026 estimate of ($0.45) represents a modest 2% deterioration from the ($0.44) loss reported in Q1 2025, suggesting analysts expect relatively stable cash burn as the company advances its clinical programs.

Key Themes Heading Into Earnings:

1. Clinical Trial Progress and Regulatory Pathway: The primary focus is on updates regarding COMP360's Phase 3 program for TRD. Investors want clarity on enrollment timelines, data readouts, and any regulatory interactions with the FDA following the Breakthrough Therapy designation. Any delays or setbacks could significantly impact the stock, while positive momentum would validate the current rally.

2. Cash Runway and Burn Rate Management: After last quarter's larger-than-expected loss, investors are scrutinizing the company's cash position and quarterly burn rate. With no revenue generation, the ability to fund operations through key clinical milestones without dilutive financing is critical. Management commentary on cash runway will be closely watched.

3. Competitive Landscape in Psychedelic Medicine: The psychedelic therapy space is becoming increasingly crowded, with multiple companies pursuing similar indications. Investors want to understand how Compass is differentiating COMP360, protecting its intellectual property, and maintaining its first-mover advantage in what could become a transformative mental health treatment category.

Analyst Commentary: Wall Street has grown notably more bullish heading into this report, with 13 of 16 analysts now rating the stock a Strong Buy—up from 10 a month ago. The average price target of $21.03 implies 124% upside from current levels, reflecting optimism about the long-term commercial potential despite near-term losses. However, the wide target range ($8.00 to $70.00) underscores the binary nature of clinical-stage biotech investing and the uncertainty around regulatory outcomes.

Part 2: Historical Earnings Performance

Compass Pathways has shown an inconsistent earnings track record over the past four quarters, with two modest beats and two misses—including a significant disappointment in the most recent quarter. In Q1 2025, the company beat estimates by 6.4%, reporting a loss of $0.44 versus the $0.47 consensus. Q2 2025 brought a small 2.7% miss at ($0.38) against a ($0.37) estimate, followed by a 5.0% beat in Q3 2025 with a ($0.38) loss versus ($0.40) expected.

The pattern broke dramatically in Q4 2025, when Compass reported a loss of $0.59 per share—a stunning 44% miss against the $0.41 consensus. This represented the company's worst quarterly performance in the dataset and raised immediate concerns about cost overruns, trial expenses, or other operational challenges. The magnitude of the miss suggests either unexpected clinical trial costs, accelerated spending on regulatory preparation, or other factors that management may not have adequately telegraphed to analysts.

Looking at the trend, losses have been volatile rather than steadily improving, ranging from $0.38 to $0.59 over the past year. The lack of a clear trajectory toward profitability is typical for clinical-stage biotechs, but the Q4 surprise has made this quarter's guidance and cash burn commentary particularly important for maintaining investor confidence.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Compass Pathways typically reports earnings before market open, meaning Day 0 captures the market's initial reaction during the first full trading session after results are released, while Day +1 reflects follow-through momentum.

Compass Pathways has exhibited significant volatility around earnings announcements, with an average absolute Day 0 move of 8.00% and an average intraday range of 13.56% on earnings day. The most dramatic reaction came in October 2024, when the stock plunged 23% on Day 0, followed by relative stability the next session. More recently, the March 2026 report saw a modest 2.3% decline on Day 0 despite the large earnings miss, followed by a 7.7% rally on Day +1—suggesting investors may have been relieved by management's commentary or saw the selloff as overdone.

The Day +1 average move of 3.64% with a 9.37% range indicates that follow-through action can be substantial, though typically less volatile than the initial reaction. Notably, several recent quarters have shown positive Day +1 moves even after mixed Day 0 performance, suggesting that investors often reassess their initial reactions after digesting the full earnings call and guidance. Given the stock's recent momentum and improved analyst sentiment, investors should prepare for potential swings in either direction, with historical patterns suggesting a Day 0 move in the high single digits is typical.

Part 2.2: Options Market Expected Move

The options market is pricing a 7.62% expected move through the May 15 expiration (3 days away), which is slightly below the stock's 8.00% average absolute Day 0 earnings move but well below the 13.56% average intraday range. This suggests options traders may be underpricing near-term volatility relative to historical earnings behavior, potentially creating opportunities for volatility strategies.

Part 3: What Analysts Are Saying

Analysts have grown decidedly more bullish on Compass Pathways heading into this earnings report, with the consensus rating standing at 4.69 out of 5.0—up from 4.62 a month ago. The current breakdown shows 13 Strong Buy ratings, 1 Moderate Buy, and 2 Hold ratings, with zero sell recommendations. Notably, the number of Strong Buy ratings has increased from 10 to 13 over the past month, reflecting improved sentiment as the company approaches this quarterly report.

The average analyst price target of $21.03 implies substantial 124% upside from the current price of $9.37, suggesting Wall Street sees significant long-term value despite near-term losses. However, the wide dispersion in targets—ranging from a low of $8.00 to a high of $70.00—underscores the binary nature of clinical-stage biotech investing. The low-end target sits just 15% below current levels, while the high-end target implies nearly 650% upside, reflecting vastly different assumptions about the probability of regulatory success and commercial potential for COMP360.

The recent strengthening in analyst sentiment, with three additional Strong Buy ratings added in the past month, suggests that Wall Street is gaining confidence in the company's clinical progress and regulatory pathway despite the Q4 earnings miss. This improved outlook heading into the Q1 report could set a high bar for management to meet or exceed expectations on both financial metrics and qualitative updates about the COMP360 program.

Part 4: Technical Picture

Compass Pathways enters this earnings report with strong technical momentum, as the Barchart Technical Opinion has shifted dramatically from a 24% Sell signal a month ago to a 100% Buy signal currently—maintained from last week's 100% Buy reading. This represents a complete reversal in technical sentiment, with the stock breaking out of a prolonged downtrend.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates powerful near-term momentum heading into earnings
• Medium-term (100% Buy): Bullish reading confirms the breakout has intermediate-term support and isn't just a short-term spike
• Long-term (100% Buy): Strong long-term buy signal suggests the stock has established a new uptrend across all timeframes

Trend Characteristics: The Strong trend with Strengthening direction indicates robust momentum that continues to build, creating a supportive technical environment for the earnings release.

The stock is trading at $9.37, positioned above its 10-day ($9.34), 20-day ($8.81), 50-day ($7.12), 100-day ($7.04), and 200-day ($6.23) moving averages, though slightly below the 5-day moving average ($9.62). This configuration shows the stock has broken decisively above all major moving averages, with the 50-day and 200-day averages now providing support levels more than 30% below current prices.

The technical setup is decidedly supportive heading into earnings, with the stock riding a powerful uptrend and all major moving averages in bullish alignment. The 50% gain from the 200-day moving average suggests strong conviction from buyers, though the slight pullback below the 5-day average indicates some near-term consolidation or profit-taking ahead of the report. Key support now sits at the 20-day moving average around $8.81, while resistance levels are less defined given the breakout. The uniformly bullish technical signals across all timeframes suggest the stock has room to run higher on positive news, though the magnitude of the recent rally also means any disappointment could trigger sharp profit-taking back toward the $8.00-$8.50 support zone.